UNSPSC 51313117: Clocinizine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C26H27CLN2.2CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AE8KM1QU3Q. European Medicines Agency schedules clocinizine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01350MIG. The term clocinizine hydrochloride is a U.S. FDA designation. Most nations, for tariff and trade purposes, schedule clocinizine hydrochloride under HS 29335995 and SITC 51576.

As of Q4 2014, CLOCINIZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Clocinizine hydrochloride bears US NLM identifiers UMLS ID C3273574 and NCI Concept Code C97696. SMILES: C1CCC(CC1)/C=C/CN2CCN(CC2)C(C3CCCCC3)C4CCC(CC4)CL.CL.CL.

UNSPSC 51313117 Clocinizine hydrochloride is a Commodity code that does not align with the recent state and local procurement activity posted under this classification. The three most recent opportunities—Seminole County's procurement of naloxone and drug deactivation systems, the Texas Health and Human Services Commission's RFI on direct-to-manufacturer prescription programs, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products—focus on naloxone supply, pharmacy benefit management infrastructure, and broad-based generic pharmaceutical distribution respectively. None of these solicitations specifically target clocinizine hydrochloride or pharmaceutical compounds within its therapeutic class. The code shows no evidence of active state and local procurement demand for this specific active pharmaceutical ingredient.

The mismatch between the code's nominal scope and the actual work being solicited under it suggests that either the posting jurisdictions have misclassified these opportunities, or clocinizine hydrochloride procurement through state and local channels is not currently represented in accessible solicitation activity. Procurement professionals should verify the appropriate UNSPSC classification for their pharmaceutical or therapeutic products before relying on this code to identify relevant state and local opportunities.